Shares of ImmuPharma plc (LON:IMM – Get Free Report) traded down 8.6% during trading on Wednesday . The stock traded as low as GBX 6.46 and last traded at GBX 6.67. 1,777,210 shares were traded during trading, a decline of 51% from the average session volume of 3,656,646 shares. The stock had previously closed at GBX 7.30.
ImmuPharma Stock Down 4.9%
The firm’s 50-day simple moving average is GBX 7.02 and its 200-day simple moving average is GBX 8.06. The firm has a market capitalization of £34.90 million, a PE ratio of -7.80 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Recommended Stories
- Five stocks we like better than ImmuPharma
- New Copper-Rich “Kraken” Zone Discovered
- Silver Is the New Oil—And the World’s Running Dry
- America’s 1776 happening again
- 3 Signs You May Want to Switch Financial Advisors
- Silver’s squeeze is tightening – opportunity forming
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
